NVO - Novo Nordisk A/S
NYSE
->
Healthcare
->
Biotechnology
Bagsvaerd,
Denmark
Type: Equity
NVO price evolution
NVO
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14392 | $30144 | $21574 | |
| Short term investments | ||||
| Net receivables | $75261 | $61964 | $70521 | |
| Inventory | $31811 | $29534 | $28020 | |
| Total current assets | $139646 | $142199 | $137551 | |
| Long term investments | ||||
| Property, plant & equipment | $90961 | $81461 | $75024 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $314486 | $300101 | $280753 | |
| Current liabilities | ||||
| Accounts payable | $25606 | $20106 | $17788 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $169655 | $172552 | $156618 | |
| Long term debt | $20528 | $19924 | $19415 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $207925 | $207110 | $190280 | |
| Shareholders' equity | ||||
| Retained earnings | $106115 | $92545 | $90025 | |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13535 | $12195 | $10720 | $12757 |
| Short term investments | $6765 | |||
| Net receivables | $75261 | $57505 | $46799 | $32184 |
| Inventory | $31811 | $24388 | $19621 | $18536 |
| Total current assets | $139646 | $108194 | $85595 | $65809 |
| Long term investments | $1441 | $1648 | ||
| Property, plant & equipment | $90961 | $66671 | $55362 | $50269 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12120.11 | |||
| Total investments | ||||
| Total assets | $314486 | $241257 | $194508 | $144922 |
| Current liabilities | ||||
| Accounts payable | $25606 | $15587 | $8870 | $5717 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $169655 | $120940 | $99516 | $70273 |
| Long term debt | $20528 | $24318 | $9654 | $443.82 |
| Total noncurrent liabilities | $1734.84 | |||
| Total debt | ||||
| Total liabilities | $207925 | $157771 | $123762 | $81597 |
| Shareholders' equity | ||||
| Retained earnings | $104522 | $80625 | $72004 | $63774 |
| Other shareholder equity | $1593 | $2411 | -$1714 | -$911 |
| Total shareholder equity | $70746 | $63325 | ||
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58731 | $54300 | ||
| Cost of revenue | ||||
| Gross Profit | $49018 | $46444 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $22105 | $22556 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $5585 | $4826 | ||
| Interest expense | $1150 | $366 | ||
| Net income | ||||
| Net income | $22478 | $19428 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $232261 | $176954 | $126946 | |
| Cost of revenue | $20932 | |||
| Gross Profit | $196496 | $148506 | $106014 | |
| Operating activities | ||||
| Research & development | $15112 | |||
| Selling, general & administrative | $36886 | |||
| Total operating expenses | $91798 | $72888 | $72470 | |
| Operating income | $54476 | |||
| Income from continuing operations | ||||
| EBIT | $54476 | |||
| Income tax expense | $20991 | $13537 | $10992 | |
| Interest expense | $2297 | -$5566 | -$390 | |
| Net income | ||||
| Net income | $83683 | $55525 | $42138 | |
| Income (for common shares) | $42138 | |||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$43892 | -$29175 | -$15932 | -$6647 |
| Financing activities | ||||
| Dividends paid | -$31767 | -$31767 | -$18337 | -$18337 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$63158 | -$53042 | -$33210 | -$20621 |
| Effect of exchange rate | -$119 | $90 | -$328 | -$263 |
| Change in cash and equivalents | $1739 | $17230 | $8921 | $2283 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $47757 | $42138 | ||
| Operating activities | ||||
| Depreciation | $5111 | $5276 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $55000 | $51951 | ||
| Investing activities | ||||
| Capital expenditures | -$6335 | -$5825 | ||
| Investments | -$5941 | -$380 | ||
| Total cash flows from investing | -$43892 | -$24918 | -$31605 | -$22436 |
| Financing activities | ||||
| Dividends paid | -$31767 | -$25303 | -$21517 | -$20121 |
| Sale and purchase of stock | ||||
| Net borrowings | $15471 | $4732 | ||
| Total cash flows from financing | -$63158 | -$51797 | -$25493 | -$32244 |
| Effect of exchange rate | -$119 | -$238 | $591 | -$456 |
| Change in cash and equivalents | $1739 | $1934 | -$1507 | -$3185 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |